| Followers | 559 |
| Posts | 39671 |
| Boards Moderated | 2 |
| Alias Born | 06/08/2006 |
Friday, July 29, 2016 8:42:50 AM
Lol. Looks like $5 coming
Recent MCRB News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/17/2026 08:50:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/16/2026 08:42:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 11:05:27 AM
- Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 03/12/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2026 10:39:08 PM
- Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates • GlobeNewswire Inc. • 03/02/2026 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 09:30:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 09:30:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 09:30:05 PM
- Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases • GlobeNewswire Inc. • 02/12/2026 12:00:00 PM
- Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy • GlobeNewswire Inc. • 01/06/2026 12:00:00 PM
- Seres Therapeutics to Participate in Piper Sandler Healthcare Conference • GlobeNewswire Inc. • 11/24/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/18/2025 09:30:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/18/2025 09:30:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/18/2025 09:30:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/05/2025 03:00:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/05/2025 12:05:23 PM
- Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/05/2025 12:00:00 PM
- Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025 • GlobeNewswire Inc. • 10/30/2025 11:00:00 AM
- Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155 • GlobeNewswire Inc. • 10/29/2025 11:00:00 AM
- Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant • GlobeNewswire Inc. • 10/14/2025 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2025 08:06:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/30/2025 08:30:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/30/2025 08:30:03 PM
- Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway • GlobeNewswire Inc. • 09/23/2025 11:00:00 AM
